CONFIDENTIAL

Comprehensive BRACAnalysis®
BRCA1 and *BRCA2* Analysis Result

PHYSICIAN	SPECIMEN	PATIENT
John Smith, MD **Comprehensive Medical Center** **1100 Grand Ave** **Away, GA 12345**	Specimen: **Blood** Draw date: **Aug 01, 2010** Accession date: **Aug 02, 2010** Report Date: **Aug 12, 2010**	Name: **Doe, Jane** Date of Birth: **April 1, 1492** Patient ID: **000000** Gender: **Female** Accession #: **00000000-BLD** Requisition #: **000000**

Test Results and Interpretation

NO MUTATION DETECTED

Test Performed:	Result:	Interpretation:
BRCA1 sequencing	No Mutation Detected	No Mutation Detected
comprehensive rearrangement	No Mutation Detected	No Mutation Detected
BRCA2 sequencing	No Mutation Detected	No Mutation Detected
comprehensive rearrangement	No Mutation Detected	No Mutation Detected

Analysis consists of sequencing of all translated exons and immediately adjacent intronic regions of the BRCA1 and BRCA2 genes, a test for five specific BRCA1 rearrangements, and a comprehensive rearrangement test of both BRCA1 and BRCA2 by quantitative PCR analysis (BRACAnalysis Rearrangement Test, BART). The classification and interpretation of all variants identified in this assay reflects the current state of scientific understanding at the time this report was issued. In some instances, the classification and interpretation of such variants may change as new scientific information becomes available.

No deleterious mutation was found in *BRCA1* or *BRCA2* in this individual by sequencing and quantitative PCR analysis. This test is designed to identify mutations in 22 exons and approximately 750 adjacent intronic base pairs of *BRCA1* as well as 26 exons and approximately 950 adjacent intronic base pairs of *BRCA2* (a total of over 17,600 base pairs analyzed). This test is also designed to detect five known *BRCA1* genomic rearrangements, including a 3.835-kb deletion involving exon 13, a 510-bp deletion involving exon 22, a 6-kb insertion involving exon 13, a 7.1-kb deletion involving exons 8 and 9, and a 26-kb deletion involving exons 14-20 (see Technical Specifications for references), as well as other duplications and deletions involving the promoter region and any exons of *BRCA1* and *BRCA2*. There are other, rare genetic abnormalities in *BRCA1* and *BRCA2* that this test will not detect. This result, however, rules out the majority of abnormalities believed to be responsible for hereditary susceptibility to breast and ovarian cancer (Ford D et al., Am J Human Genetics 62:676-689, 1998). If this individual has never had breast or ovarian cancer, it is recommended that testing an affected relative be considered to help clarify the clinical significance of this individual's negative test result.

Please contact Myriad Professional Support at 1-800-469-7423 to discuss any questions regarding this result.

Director Name Here
Qualifications Here

Director Name Here
Qualifications Here

These test results should only be used in conjunction with the patient's clinical history and any previous analysis of appropriate family members. It is strongly recommended that these test results be communicated to the patient in a setting that includes appropriate counseling. The accompanying Technical Specifications summary describes the analysis, method, performance characteristics, nomenclature, and interpretive criteria of this test. This test may be considered investigational by some states. This test and its performance characteristics were determined by Myriad Genetic Laboratories. It has not been reviewed by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary.